Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
2 Reasons Why Novavax Investors Should Be Cautious
02:53pm, Tuesday, 29'th Mar 2022 The Motley Fool
There's reason to believe things aren't going exactly as planned.
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
11:41am, Tuesday, 29'th Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Pfizer Announces Positive Results From Second Late-Stage Study Of Ulcerative Colitis Drug
Pfizer, Inc.
Pfizer’s etrasimod hits goals again in ulcerative colitis study
11:25am, Tuesday, 29'th Mar 2022 MarketWatch
Pfizer Inc. on Tuesday said a second Phase 3 study of its recently acquired investigational drug etrasimod met the main endpoints in the treatment of moderately to severely active ulcerative colitis,
Should You Buy Moderna? Look at These 2 Charts First.
10:00am, Tuesday, 29'th Mar 2022 The Motley Fool
They offer us clues about near-term and long-term revenue.
FDA Revises EUA of Glaxo (GSK) & Vir's (VIR) COVID Therapy
03:41pm, Monday, 28'th Mar 2022 Zacks Investment Research
The FDA restricts the use of sotrovimab, Glaxo (GSK)/Vir's (VIR) COVID therapy, in several states and territories based on the latest data that does not support the therapy's effectiveness against a d
Are These 2 Rivals Beating Pfizer and Moderna?
10:00am, Monday, 28'th Mar 2022 The Motley Fool
They're winning when it comes to orders.
Which Company Has the Biggest COVID Program? The Answer Isn't Moderna.
12:00pm, Sunday, 27'th Mar 2022 The Motley Fool
Another player has stuffed its pipeline with many coronavirus candidates.
Is Vaxart the Next Moderna?
03:15pm, Saturday, 26'th Mar 2022 The Motley Fool
The similarities are striking.
The U.S. is talking about a second round of COVID-19 booster shots, and it's going to be even more complicated than last year
03:02pm, Saturday, 26'th Mar 2022 MarketWatch
Health officials are already talking about rolling out a fourth dose of the COVID-19 vaccine in the U.S. although there are still questions about the efficacy, timing, availability, and formulation of
How Pfizer's $6.7 Billion Arena Pharmaceuticals Buyout Could Work for Investors
09:34am, Saturday, 26'th Mar 2022 The Motley Fool
Here's why America's largest pharmaceutical company splashed out on an experimental treatment you've probably never heard of.
These 3 Stocks Aren't Large Caps Yet, but They Each Could Make $1 Billion in Sales in 2022
08:00pm, Friday, 25'th Mar 2022 The Motley Fool
Looking for small healthcare companies with huge revenue opportunities? Try these.
Airport-based study found first U.S. case of BA.2 subvariant of omicron in December
05:43pm, Friday, 25'th Mar 2022 MarketWatch
An airport-based COVID-19 surveillance program detected the first known U.S. case of the highly transmissible omicron BA.2 subvariant in December, according to a new study that was funded by the Cente
Pfizer's (PFE) RSV Jab Gets Another Breakthrough Therapy Tag
03:03pm, Friday, 25'th Mar 2022 Zacks Investment Research
The FDA bestows another Breakthrough Therapy status to Pfizer's (PFE) RSV vaccine candidate, RSVpreF, for the prevention of RSV in older adults.
1 Green Flag for Eli Lilly Investors in 2022 -- and 1 Red Flag
03:00pm, Friday, 25'th Mar 2022 The Motley Fool
Does the upside outweigh the downside for this pharma giant?
2 Green Flags for Pfizer's Future
02:23pm, Friday, 25'th Mar 2022 The Motley Fool
Could Pfizer be one of the best pharma giants to invest in right now?
